Which markets do you export to?

Products are exported to South America, Southeast Asia, Africa, Oceania, and the Middle East.

Is the manufacturer GMP certified?

Yes, the company has GMP approval by the SFDA of China.

Western Medicine Metronidazole Injection / Infusion

Name: Western Medicine Metronidazole Injection / Infusion
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 1938987915

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.14-0.18

20,000 Pieces

Sample price:US$0.10/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Injection

Suitable for

Elderly, Adult

State

Liquid

Shape

Injection

Type

Injection

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

Guoyaozhunzi H13022486

Transport Package

Plastic Bottle

Specification

100ml 250ml

Trademark

SHIMEN

Origin

Hebei

HS Code

3004909099

Production Capacity

1000000

Key features

Proven Efficacy Against Anaerobes: Potent nitro-imidazole derivative that inhibits DNA synthesis in anaerobic organisms.

Established Manufacturer: Produced by Shijiazhuang No.4 Pharmaceutical Co., Ltd., established in 1948 with GMP approval.

High Production Capacity: Yearly output exceeds 1200 million bottles, including 40 million soft plastic bottles.

Global Market Presence: Products sold to South America, Africa, Asia, Oceania, and the Middle East.

Flexible Payment Terms: Accepts LC (Letter of Credit) and T/T (Telegraphic Transfer) for secure transactions.

Multiple Packaging Options: Available in 500ml, 250ml, and 100ml soft plastic bottles for IV solutions.

Comprehensive Product Range: Manufacturer offers over 100 kinds and specifications across 7 medicine series.

Fast Peak Season Lead Time: Average lead time is one month during peak seasons for timely delivery.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤11.83hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.